Visual Inspection with Acetic Acid for Cervical Cancer Screening Outside of Low-resource Settings
Overview
Authors
Affiliations
Objectives: To assess visual inspection with acetic acid (VIA) as a screening tool for use in a well-equipped health center in Peru, to evaluate VIA as an alternative or adjunct to the Papanicolaou (Pap) smear, and to determine if VIA can play a role in settings other than low-resource ones.
Methods: This was a prospective study of 1 921 asymptomatic women living in Lima, Peru, carried out in 1999 and 2000. The study was performed at a cancer center equipped with the latest-generation technology and highly trained oncologists. The women underwent a complete clinical evaluation, including a Pap smear and VIA. Participants with any positive test were referred for colposcopy and biopsy.
Results: More women tested positive by VIA than on the Pap smear (6.9% vs. 4.2%; P = 0.0001). There were 35 women with histologic cervical intraepithelial neoplasia grade 1 (CIN 1); of these, 15 were detected by Pap and 20 by VIA (P = 0.4). A diagnosis of CIN 2 or 3 (CIN 2-3) was confirmed in a total of 13 cases; Pap detected 5 of the cases and VIA 11 of the cases (P = 0.06). The positive predictive value for detection of CIN 2+ was 8.3% for VIA and 6.3% for Pap (P = 0.5). Most importantly, while only 2.3% of patients with a positive VIA were lost to follow-up before colposcopy, that was true for 26.3% of the women with a positive Pap smear (P < 0.0001).
Conclusions: VIA is useful for detection of precursor lesions of cervical cancer not only in low-resource settings but also in well-equipped health centers and cancer centers. In these non-low-resource settings, VIA has a positive predictive value comparable to the conventional Pap smear, but it is more likely to achieve earlier diagnosis, follow-up, and treatment than cytology-based screening.
Tassembedo S, Winter C, Traore I, Ouattara A, Sawadogo M, Meda N Pan Afr Med J. 2023; 45:135.
PMID: 37790161 PMC: 10543905. DOI: 10.11604/pamj.2023.45.135.36933.
Policy Considerations to Promote Equitable Cervical Cancer Screening and Treatment in Peru.
Thoumi A, Bond S, Dotson M, Krieger M, Garcia P, Ramanujam N Ann Glob Health. 2021; 87(1):116.
PMID: 34900616 PMC: 8622178. DOI: 10.5334/aogh.3442.
Mensah K, Kabore C, Zeba S, Bouchon M, Duchesne V, Pourette D BMC Womens Health. 2021; 21(1):251.
PMID: 34162367 PMC: 8220722. DOI: 10.1186/s12905-021-01392-4.
Levy J, de Preux M, Kenfack B, Sormani J, Catarino R, Tincho E Cancer Med. 2020; 9(19):7293-7300.
PMID: 32757469 PMC: 7541141. DOI: 10.1002/cam4.3355.
Mueller J, Lam C, Dahl D, Asiedu M, Krieger M, Bellido-Fuentes Y BJOG. 2018; 125(10):1321-1329.
PMID: 29893472 PMC: 6115285. DOI: 10.1111/1471-0528.15326.